Skip to content

Immix Biopharma, Inc. IMMX Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-74.4%+37.0pp-54.9%+90.8pp-182.5%-65.2pp-162%-59.5pp-111.4%-19.7pp
Return on assets-60.4%+16.7pp-46%+54.8pp-104.2%-12.3pp-104%-18.3pp-77.1%-0.5pp
Liquidity
Current ratio8.8×+7.0×10×+7.7×1.5×-1.9×1.2×-5.8×1.8×-4.0×
Quick ratio8.8×+7.0×10×+7.7×1.5×-1.9×1.2×-5.8×1.8×-4.0×
Cash ratio7.5×+5.8×9.3×+7.3×1.5×-1.5×1.2×-5.0×1.7×-3.5×
Leverage
Debt-to-equity-0.1×-0.1×0.1×0.2×0.1×
Debt-to-assets0.0×0.0×0.1×0.1×0.1×
Per Share
Book value per share$1.52+372%$2.85+507%$0.26-56.6%$0.16-81.3%$0.32-72.9%
Valuation
Market capitalization$691.97M+1,008%$275.6M+355%$68.27M+55.7%$62.45M+9.6%$46.57M-35.3%
Enterprise value$613.75M+1,190%$182.74M+316%$53.43M$51.85M$31.71M
Price / book8.2×+1.7×2.9×-1.6×8.3×+5.8×13.4×+11.0×4.9×+2.3×
Free cash flow yield-4.7%+16.7pp-8.9%-22.6%-21.6%
Earnings yield-5%+28.4pp-10.7%+25.0pp-34.5%+15.4pp-37%-3.7pp-44.9%-19.6pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immix Biopharma, Inc.'s ratios come from?
Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.